Allianz Asset Management GmbH Acquires 2,815 Shares of BioNTech SE Sponsored ADR $BNTX

Key Points

• Allianz Asset Management GmbH increased its stake in BioNTech SE by 2.3%, acquiring an additional 2,815 shares during the second quarter.
• Research analysts maintain a Moderate Buy rating for BioNTech, with average price targets ranging from $121.00 to $150.00.
• In its latest quarterly earnings report, BioNTech reported a revenue of $306.46 million, significantly exceeding analyst estimates.

Allianz Asset Management GmbH raised its holdings in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 2.3% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 123,495 shares of the company's stock after purchasing an additional 2,815 shares during the period. Allianz Asset Management GmbH owned 0.05% of BioNTech worth $13,149,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the business. Goodman Advisory Group LLC purchased a new position in BioNTech during the 1st quarter worth $105,000. Vontobel Holding Ltd. grew its stake in BioNTech by 2.3% during the 1st quarter. Vontobel Holding Ltd. now owns 21,882 shares of the company's stock worth $1,993,000 after buying an additional 497 shares during the last quarter. OneDigital Investment Advisors LLC purchased a new position in BioNTech during the 1st quarter worth $288,000. GF Fund Management CO. LTD. grew its stake in BioNTech by 22.0% during the 1st quarter. GF Fund Management CO. LTD. now owns 2,514 shares of the company's stock worth $229,000 after buying an additional 453 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its stake in BioNTech by 18,892.9% during the 1st quarter. Bank of New York Mellon Corp now owns 698,368 shares of the company's stock worth $63,593,000 after buying an additional 694,691 shares during the last quarter. Institutional investors and hedge funds own 15.52% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on BNTX shares. Weiss Ratings restated a "sell (d-)" rating on shares of BioNTech in a research note on Tuesday, October 14th. JPMorgan Chase & Co. boosted their target price on BioNTech from $116.00 to $121.00 and gave the stock a "neutral" rating in a research note on Monday, September 22nd. HC Wainwright restated a "buy" rating and set a $136.00 target price on shares of BioNTech in a research note on Monday, September 8th. Wells Fargo & Company set a $150.00 target price on BioNTech and gave the stock an "overweight" rating in a research note on Tuesday, August 5th. Finally, Bank of America lifted their price target on BioNTech from $126.00 to $134.00 and gave the stock a "buy" rating in a research report on Tuesday, August 5th. Ten investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, BioNTech currently has an average rating of "Moderate Buy" and an average price target of $134.32.

BioNTech Stock Performance

Shares of BNTX opened at $107.95 on Tuesday. The stock has a market cap of $25.95 billion, a P/E ratio of -67.47 and a beta of 1.45. The stock has a 50-day moving average of $103.73 and a two-hundred day moving average of $104.18. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.48 and a current ratio of 8.61. BioNTech SE Sponsored ADR has a one year low of $81.20 and a one year high of $129.27.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.41) by ($0.19). The company had revenue of $306.46 million during the quarter, compared to analyst estimates of $161.26 million. BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. The business's quarterly revenue was up 102.6% compared to the same quarter last year. During the same period last year, the firm earned ($3.36) EPS. BioNTech has set its FY 2025 guidance at EPS. As a group, research analysts predict that BioNTech SE Sponsored ADR will post -3.88 EPS for the current year.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.

Want to see what other hedge funds are holding BNTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.